Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS surgical system for spine surgery. This new technology aims to provide real-time visualization of anatomical motion during procedures, potentially reducing the need for repeated imaging and streamlining the surgical workflow. While the stock’s valuation is seen as a premium, analysts have set an average price target of $110.29, suggesting confidence in its growth prospects.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Medtronic Wins FDA Nod For Spine Surgery Tech Designed To Cut Repeat Imaging
Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS surgical system for spine surgery. This new technology aims to provide real-time visualization of anatomical motion during procedures, potentially reducing the need for repeated imaging and streamlining the surgical workflow. While the stock’s valuation is seen as a premium, analysts have set an average price target of $110.29, suggesting confidence in its growth prospects.